Combination therapy with Bosentan and Sildenafil improves Raynaud’s phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis

Clinical Rheumatology

Volumn 35, Issue 1, 2016, Pages 127-132

  Bellando Randone, S ^a   Lepri, G ^a   Bruni, C ^a   Blagojevic, J ^a   Radicati, A ^a   Cometi, L ^a   De Paulis, A ^b   Matucci Cerinic, M ^a   Guiducci, S ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bosentan; Microvasculature; Sildenafil; Systemic sclerosis

Indexed keywords

BOSENTAN; SILDENAFIL; SULFONAMIDE; VASODILATOR AGENT;

ADULT; ARTICLE; CAPILLAROSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NAILFOLD VIDEOCAPILLAROSCOPY; PRIORITY JOURNAL; QUALITY OF LIFE; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT DURATION; AGED; ANGIOSCOPY; CAPILLARY; COMBINATION DRUG THERAPY; DRUG EFFECTS; MIDDLE AGED; NAIL; PATHOPHYSIOLOGY; RAYNAUD DISEASE; RETROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; CAPILLARIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROSCOPIC ANGIOSCOPY; MICROVESSELS; MIDDLE AGED; NAILS; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SILDENAFIL CITRATE; SULFONAMIDES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84954404271     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3119-3     Document Type: Article

References (25)

1. Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65(8):1953–62
2. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C et al (2011) EUSTAR group preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis 70(3):476–81
3. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis 68(5):620–8
4. MatucciCerinic M, Kahaleh MB (2002) Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford) 41:843–7
5. Roustit M, Blaise S, Allanore Y et al (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696–1699
6. Fries R, Shariat K, von Wilmowsky H et al (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–5
7. Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, Burmester G, Riemekasten G (2010) Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 69(8):1475–8
8. Abraham D, Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S2
9. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators et al (2008) Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 67(9):1222–8
10. Korn J, Mayes M, Matucci-Cerinic M et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with Bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–93
11. Matucci-Cerinic M, Denton C, Furst D et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–8
12. Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, Paolino S, Seriolo B, Cimmino M, Sulli A (2014) Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol 41(5):881–6
13. Guiducci S, Bellando-Randone S, Bruni C et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725
14. Cutolo M, Zampogna G, Vremis L et al (2013) Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatology 40:40–45
15. Van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747–55
16. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
17. Valentini G, Cuomo G, Abignano G et al (2011) Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 50:317–23
18. Cutolo M, Pizzorini C, Meroni M et al (2010) The role of nailfold videocapillaroscopy in Raynaud’s phenomenon monitoring and early diagnosis of systemic sclerosis. Reumatismo 62:237–47
19. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S (2013) Very early versus early disease: the evolving definition of the many faces of systemic sclerosis. Ann Rheum Dis 72:319–21
20. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L et al (2014) Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73(12):2087–93
21. Korn JH, Mayes M, MatucciCerinic M et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–93
22. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–8
23. Moinzadeh P, Hunzelmann N, Krieg T (2011) Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. J Am Acad Dermatol 65:e102–4
24. Catarsi E, Doveri M, Tavoni A (2013) Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers. Reumatismo 65(2):79–81
25. Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M (2014) Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford) 53(6):975–87